中国普通外科杂志2026，Vol.35Issue(1)：53-59,7.DOI:10.7659/j.issn.1005-6947.250551
原发性肝癌转化治疗进展与思考
Advances and perspectives on conversion therapy for primary liver cancer
摘要
Abstract
Primary liver cancer,specifically referring to hepatocellular carcinoma(hereafter referred to as HCC)in this article,is one of the malignant tumors with relatively high incidence and mortality in China.Because most patients are diagnosed at an intermediate or advanced stage,or present with impaired hepatic reserve due to underlying liver cirrhosis,opportunities for curative surgical resection are limited.In recent years,drawing on therapeutic experience from colorectal cancer,conversion therapy has attracted considerable attention in the field of liver cancer as a comprehensive treatment strategy aimed at achieving radical resection.Through systemic therapy,locoregional treatment,or their combination,this approach seeks to convert initially unresectable HCC into tumors amenable to radical resection,thereby improving long-term survival outcomes.With the rapid development of targeted therapies,immunotherapy,and locoregional treatment modalities,conversion therapy has become a major research focus in liver cancer management in China and has achieved encouraging progress in clinical practice.Nevertheless,substantial controversies remain regarding patient selection,the value of surgery after conversion,optimal timing of resection,and postoperative management.In this article,recent advances in oncological conversion therapy are systematically reviewed and critically appraised,with the aim of promoting conceptual consensus and standardized clinical implementation of conversion therapy,ultimately improving the overall treatment outcomes of patients with intermediate to advanced hepatocellular carcinoma.关键词
癌,肝细胞/转化治疗/新辅助疗法/免疫疗法Key words
Carcinoma,Hepatocellular/Conversion Therapy/Neoadjuvant Therapy/Immunotherapy分类
医药卫生引用本文复制引用
袁声贤,丁冬阳,周伟平..原发性肝癌转化治疗进展与思考[J].中国普通外科杂志,2026,35(1):53-59,7.基金项目
国家自然科学基金资助项目(82473341,82573583). （82473341,82573583）
